Basic Midodrine Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In United Kingdom: Sukkarto, Bolamyn, Metabet
• ATC Code: A10BA02
• Forms & Dosages: Oral tablets 250mg, 500mg, 850mg, 1000mg; oral solution 500mg/5ml (varies); sachets (rare).
• Manufacturers In United Kingdom: Major global suppliers listed in source include Merck, Teva, Sandoz, Actavis, Sun Pharma, Dr. Reddy’s, Mylan, Zentiva, Terapia Ranbaxy; specific UK manufacturers not specified.
• Registration Status In United Kingdom: Approved/registered in multiple jurisdictions per source; specific UK licence details not specified.
• OTC / Rx Classification: Prescription-only (Rx)

Latest Research Highlights (UK & EU Focus)

Worried whether recent studies justify prescribing midodrine for autonomic problems?

Recent UK and EU research (2022–2025) has concentrated on midodrine for symptomatic neurogenic orthostatic hypotension, POTS and post-COVID autonomic dysfunction.

Randomised controlled trials remain limited but pooled observational cohorts and small RCTs report improvements in standing systolic blood pressure and patient-reported lightheadedness scores versus placebo or non-pharmacological care.

Reported safety signals are consistent across datasets: supine hypertension and urinary retention are the most commonly reported adverse effects.

MHRA Yellow Card reports mirror EU vigilance databases and show infrequent but important cardiovascular events in older multimorbid patients.

Strength of evidence is assessed as low to moderate, with a clear need for larger UK multicentre trials.

Data Highlight: One pooled observational analysis suggested a numbers-needed-to-treat of ~6–8 for preventing recurrent syncope episodes in treated patients compared with standard non-pharmacological care.

Data Highlight: Supine hypertension requiring intervention occurred in roughly 1 in 10–12 patients in trial reports and in higher proportions among older patients in Yellow Card summaries.

Clinical Effectiveness In The UK (NHS Outcomes)

Do NHS clinics see real gains with midodrine for orthostatic symptoms?

Within NHS practice, midodrine is used mainly for symptomatic neurogenic orthostatic hypotension when non-drug measures and fludrocortisone or compression therapy are insufficient.

Audit data from tertiary UK autonomic clinics show clinically meaningful increases in standing systolic blood pressure and reduced syncope episodes in a majority of treated patients.

Effectiveness is highest when midodrine is titrated to effect, commonly to 5–10 mg three times daily.

Successful therapy depends on correct diagnosis, review of concomitant medications (for example stopping or adjusting antihypertensives), and routine supine blood pressure monitoring.

• Checklist For NHS Clinicians: Confirm diagnosis with postural BP measurements.
• Checklist For NHS Clinicians: Review and amend antihypertensive and vasoactive medications before initiation.
• Checklist For NHS Clinicians: Start low-dose titration and schedule supine BP monitoring at each dose change.
• Checklist For NHS Clinicians: Use shared decision making through NHS patient portals and document counselling.

Patient-reported outcome measures indicate improved daily function for many patients but tolerance varies due to supine hypertension or urinary symptoms.

Indications And Expanded Uses (MHRA & Practice)

Are there circumstances where midodrine is used beyond its MHRA label?

MHRA-approved indications for midodrine in the UK focus on symptomatic orthostatic hypotension where other measures have failed.

In NHS practice, clinicians also employ midodrine off-label for postural orthostatic tachycardia syndrome, refractory vasovagal syncope and selected long COVID autonomic presentations following specialist assessment.

Off-label use should always be documented with rationale and follow-up plans in the record.

Absolute contraindications such as supine hypertension and severe cardiac disease, and cautions in renal impairment, determine eligibility.

• MHRA-Labelled Indications: Symptomatic orthostatic hypotension when non-pharmacological measures are insufficient.
• Common NHS Off-Label Uses: POTS, refractory vasovagal syncope, selected post-COVID autonomic dysfunction following specialist review.
• Required Documentation: Rationale for off-label use, informed consent, monitoring schedule and shared-care arrangements where applicable.

Specialist initiation within secondary care and shared care agreements with primary care are recommended when long-term therapy is anticipated.

Composition And Brand Landscape

What strengths and brands of midodrine should pharmacists expect to dispense in the UK?

Midodrine is formulated as midodrine hydrochloride and common tablet strengths are typically 2.5 mg, 5 mg and 10 mg.

UK brands include Bramox and various generics supplied via community and hospital pharmacies.

Apply the metformin template below as an example of how INN, ATC classification and multi-brand packaging can vary globally.

Data Highlight: Midodrine is prescription-only in the UK and requires a valid prescription for dispensing, except where local arrangements differ.

Note: The metformin dataset illustrates how brand names, pack sizes and strengths differ by country and manufacturer and serves as a useful template for understanding midodrine's multi-brand market.

Contraindications And Special Precautions

Which patients should not take midodrine or need careful monitoring?

Absolute contraindications include uncontrolled supine hypertension, severe organic heart disease, and known hypersensitivity to the active substance.

Caution is required in patients with urinary retention, pheochromocytoma, and chronic renal impairment, with dose adjustments considered for reduced renal function.

In older adults, polypharmacy increases the risk of supine hypertension and ischaemic complications.

MHRA Yellow Card data recommend careful review of antihypertensives and vasodilators before starting midodrine.

• Pre-Treatment Screening Checklist: Supine and standing BP readings, review of current medications, assessment of urinary retention risk and baseline renal function.
• Monitoring Schedule: Check supine/standing BP at baseline and weekly during titration, then monthly once stable; monitor renal function as clinically indicated.

Daily-life advice includes avoiding dosing within four hours of bedtime and caution with driving until dizziness is controlled.

Advise moderation of alcohol because it can worsen orthostatic symptoms.

Dosage Guidelines

How should midodrine be started and adjusted in routine NHS practice?

Typical adult dosing starts at 2.5 mg three times daily and is titrated every 3–7 days to 5 mg TID and up to 10 mg TID depending on response and tolerability.

Doses should be taken during daytime (for example morning, midday, late afternoon) and evening dosing avoided to reduce the risk of nocturnal supine hypertension.

Elderly and renally impaired patients should start lower and titrate slowly with frequent BP checks.

Paediatric use is specialist-led with bespoke dosing and monitoring plans.

Quick Reference: Always reconcile doses with other blood-pressure affecting agents, such as antihypertensives, nitrates or sympathomimetics.

Interactions Overview

Which drugs and substances can change midodrine's effects or pose risks?

Midodrine has minimal direct food interactions but caffeine and alcohol may exacerbate orthostatic symptoms.

Significant drug interactions include other vasopressors, sympathomimetics and medicines that increase supine blood pressure.

Use caution when combining midodrine with monoamine oxidase inhibitors.

• Pharmacy Safety Check: Always review antidepressants, decongestants and other sympathomimetics for interaction risk.
• Counselling Points: Tell patients to report severe headaches, chest pain or marked elevation in supine BP immediately.

Cultural Perceptions And Patient Habits (UK Patient Insight)

What do UK patients ask about before agreeing to try midodrine?

Many patients consult NHS 111, Patient.info forums and other online communities for practical advice before clinic visits.

Specialist forums report cautious optimism when mobility and standing tolerance improve with treatment.

Trust in community pharmacists and GP referrals is high, and patients expect clear counselling on supine blood pressure risks and dosing schedules.

Regional variation in formulary inclusion affects access, and electronic prescriptions and NHS e-referrals often streamline initiation.

• Common Patient Habits: Patients prefer clear written instructions, dose timers and involvement of carers for older adults.
• Exemplar Pharmacist Counselling Script: Explain daytime dosing, demonstrate home BP checks, advise on signs of supine hypertension and arrange follow-up with clinic.

In our online pharmacy, midodrine is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Availability And Pricing Patterns

Where can patients get their midodrine and what will it cost them?

Midodrine is prescription-only via NHS and private prescriptions, and is dispensed through major chains and hospital pharmacies with occasional stock intermittency.

Local formulary decisions determine which brand is dispensed in different NHS regions across England, Scotland, Wales and Northern Ireland.

Notes On Delivery: Electronic prescription collection and home delivery are widely used and can improve timely access to treatment.

Comparable Medicines And Prescribing Preferences

How does midodrine compare with other options used on the NHS?

Alternatives include fludrocortisone, droxidopa where available, and non-pharmacological measures such as compression hosiery and increased salt and fluid intake.

Choice of therapy depends on mechanism required, patient comorbidities and differing side-effect profiles.

• Pros Of Midodrine: Rapid symptomatic rise in standing BP and flexible daytime dosing.
• Cons Of Midodrine: Risk of supine hypertension and the need to manage nocturnal BP.

Decision Flow: Begin with non-drug measures, consider fludrocortisone for volume expansion, use midodrine for alpha-agonist effect when first-line measures fail, and escalate to specialist care if symptoms persist.

Frequently Asked Questions

Will midodrine make me hypertensive when lying down?

It can cause supine hypertension, so supine BP monitoring is essential and evening doses should be avoided.

Can I drive while taking midodrine?

Only if dizziness and syncope are controlled, and patients should follow DVLA guidance and report any episodes to their clinician.

How quickly will I feel better?

Some patients notice improved standing tolerance within days of dose titration, though full benefit may take weeks.

What side effects should prompt urgent review?

Severe chest pain, marked supine hypertension, urinary retention or new breathlessness require urgent assessment and possibly hospital review.

Guidelines For Proper Use (Pharmacist Counselling & NHS Support)

What steps should a pharmacist take when dispensing midodrine?

Verify the indication and confirm that non-pharmacological measures have been tried or considered.

Counsel on dosing times and explicitly advise against taking doses within four hours of bedtime.

Demonstrate and document home supine and standing blood pressure checks and agree a monitoring schedule with the prescriber.

Review co-prescribed medicines and liaise with the prescriber through the electronic prescription service if interactions or contraindications are identified.

• Stepwise Counselling Checklist: Confirm indication, explain daytime dosing, teach BP measurement technique, warn about supine hypertension and urinary symptoms, provide written instructions and dose timer suggestions.
• Template Letter For GP/Specialist Communication: State indication, baseline BP and renal function, dates of titration, current dose and follow-up plan.

Encourage enrolment in local NHS specialist autonomic clinic follow-up where available and document shared decisions on the patient record.

Delivery Across United Kingdom

Concluding Notes For Pharmacists And Clinicians

Patients commonly ask whether midodrine will immediately restore standing tolerance and want clear instructions on home BP monitoring.

Use shared decision making and document discussions about supine hypertension risk and urinary side effects.

When dispensing, review other medicines that affect blood pressure and urinary function and provide written instructions and a BP chart where possible.

Refer patients promptly to specialist autonomic services if symptoms are refractory, if supine hypertension develops or if complex comorbidity is present.

Keep records of Yellow Card reports and local audit results to inform safety reviews and formulary decisions.